PT942740E - Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf - Google Patents
Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnfInfo
- Publication number
- PT942740E PT942740E PT97953156T PT97953156T PT942740E PT 942740 E PT942740 E PT 942740E PT 97953156 T PT97953156 T PT 97953156T PT 97953156 T PT97953156 T PT 97953156T PT 942740 E PT942740 E PT 942740E
- Authority
- PT
- Portugal
- Prior art keywords
- tnf
- protein
- ligaction
- treatment
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3258796P | 1996-12-06 | 1996-12-06 | |
US3635597P | 1997-01-23 | 1997-01-23 | |
US3931597P | 1997-02-07 | 1997-02-07 | |
US5202397P | 1997-07-09 | 1997-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT942740E true PT942740E (pt) | 2004-01-30 |
Family
ID=27488013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT97953156T PT942740E (pt) | 1996-12-06 | 1997-12-08 | Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf |
Country Status (12)
Country | Link |
---|---|
US (4) | US6306820B1 (pt) |
EP (1) | EP0942740B1 (pt) |
JP (1) | JP2001513754A (pt) |
AT (1) | ATE247974T1 (pt) |
AU (1) | AU5696198A (pt) |
CA (1) | CA2273850A1 (pt) |
DE (1) | DE69724451T2 (pt) |
DK (1) | DK0942740T3 (pt) |
ES (1) | ES2207759T3 (pt) |
HK (1) | HK1022440A1 (pt) |
PT (1) | PT942740E (pt) |
WO (1) | WO1998024463A2 (pt) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040120952A1 (en) * | 2000-08-07 | 2004-06-24 | Centocor, Inc | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
US6770279B1 (en) | 1992-10-08 | 2004-08-03 | The Kennedy Institute Of Rheumatology | TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis |
AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
US7091181B2 (en) | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
US20020028798A1 (en) * | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
US20040127884A1 (en) * | 1994-12-12 | 2004-07-01 | Omeros Corporation | Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
US7067144B2 (en) * | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
WO2000027421A2 (en) * | 1998-11-06 | 2000-05-18 | The Schepens Eye Research Institute, Inc. | LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE |
USRE45976E1 (en) * | 1999-02-24 | 2016-04-19 | Tact Ip, Llc | Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally |
US8119127B2 (en) * | 1999-02-24 | 2012-02-21 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
US6982089B2 (en) | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
WO2000062790A2 (en) * | 1999-04-19 | 2000-10-26 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
DK1180159T3 (da) * | 1999-05-28 | 2008-11-17 | Targeted Genetics Corp | Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser |
ES2308985T3 (es) * | 1999-07-21 | 2008-12-16 | Omeros Corporation | Disoluciones y procedimientos para la inhibicion del dolor, inflamacion y degradacion del cartilago. |
EP1237575B1 (en) * | 1999-12-14 | 2008-08-06 | Genentech, Inc. | Tnf-alpha antagonist and lfa-1 antagonist for treating rheumatoid arthritis |
US7687461B2 (en) * | 2000-03-02 | 2010-03-30 | Xencor, Inc. | Treatment of TNF-α related disorders with TNF-α variant proteins |
US20070172449A1 (en) * | 2000-03-02 | 2007-07-26 | Xencor, Inc. | TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS |
US7244823B2 (en) * | 2000-03-02 | 2007-07-17 | Xencor | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders |
IL152450A0 (en) * | 2000-05-12 | 2003-05-29 | Genzyme Corp | COMPOUNDS HAVING TNF-alpha SIGNAL MODULATING ACTIVITY |
AU2001271341A1 (en) * | 2000-06-20 | 2002-01-02 | Arthur L. Herbst | COX-2 inhibitors and the prevention of the side effects of radiation therapy |
US20060018907A1 (en) * | 2000-08-07 | 2006-01-26 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
AU2001286701A1 (en) * | 2000-08-31 | 2002-03-13 | Genzyme Biosurgery Corporation | Hyaluronan-based antiadhesion compositions, their preparation and use |
US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
PL222211B1 (pl) | 2001-06-26 | 2016-07-29 | Amgen Fremont Inc | Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza |
DE10132308A1 (de) * | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Kombinationspräparat zur Therapie von immunologischen Erkrankungen |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
WO2004035762A2 (en) * | 2002-10-17 | 2004-04-29 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulation and sustained release of biologically active polypeptides |
PT1567138E (pt) * | 2002-11-21 | 2011-04-11 | Genzyme Corp | Utilização de derivados de diamida para inibição de rejeição crónica de transplante |
AU2003291143A1 (en) * | 2002-11-21 | 2004-06-18 | Genzyme Corporation | Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance |
BRPI0407649A (pt) | 2003-02-28 | 2006-02-21 | Ares Trading Sa | formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação |
US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
CN1968700A (zh) * | 2004-04-15 | 2007-05-23 | 阿尔克姆斯有限公司 | 聚合物基的持续释放装置 |
US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
US20080051365A1 (en) * | 2004-12-02 | 2008-02-28 | Can-Fite Biopharma Ltd. | Treatment of Inflammation |
ES2327435T3 (es) | 2004-12-02 | 2009-10-29 | Can-Fite Biopharma Ltd. | Un marcador biologico para la imflamacion. |
US8236306B2 (en) * | 2004-12-18 | 2012-08-07 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
WO2006093784A2 (en) * | 2005-02-25 | 2006-09-08 | Mutual Pharmaceutical Company, Inc. | Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents |
AR056806A1 (es) | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
WO2011068993A1 (en) * | 2009-12-02 | 2011-06-09 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life of fc fusion proteins. |
WO2012170938A1 (en) | 2011-06-08 | 2012-12-13 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life |
CN103965357B (zh) | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
EP3085709B1 (en) | 2014-12-28 | 2019-08-21 | Genor Biopharma Co., Ltd | Humanized anti-human rankl antibody, pharmaceutical composition and use thereof |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
IN150740B (pt) | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
IL80005A (en) | 1986-09-10 | 1992-11-15 | Yeda Res & Dev | Compositions for modulating the effect of tnf and il-1 |
US5512544A (en) | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
IL90339A (en) | 1989-05-18 | 1996-10-16 | Yeda Res & Dev | Anti-cytotoxic protein and its purification |
US5153265A (en) | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
GB8806339D0 (en) | 1988-03-17 | 1988-04-13 | Hoffmann La Roche | Monoclonal antibodies |
GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
US5811261A (en) | 1988-09-12 | 1998-09-22 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
JPH04502011A (ja) | 1988-11-23 | 1992-04-09 | ジェネンテク,インコーポレイテッド | ポリペプチド誘導体 |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
AU636608B2 (en) | 1989-05-18 | 1993-05-06 | Yeda Research And Development Co. Ltd. | Tumor necrosis factor binding protein II, it's purification and antibodies thereto |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
WO1991003553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | TUMOR NECROSIS FACTOR-α AND -β RECEPTORS |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
ATE194384T1 (de) | 1989-09-12 | 2000-07-15 | Hoffmann La Roche | Tnf-bindende proteine |
EP0433900B1 (en) | 1989-12-13 | 1995-09-20 | Yeda Research And Development Company Limited | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
GB2246569A (en) | 1990-06-15 | 1992-02-05 | Charing Cross Sunley Research | Tumour necrosis factor - alpha binding protein |
WO1992001002A1 (fr) | 1990-07-11 | 1992-01-23 | Teijin Limited | Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation |
GB9015908D0 (en) | 1990-07-19 | 1990-09-05 | Celltech Ltd | Multivalent immunoglobulin |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
GB9023783D0 (en) * | 1990-11-01 | 1990-12-12 | Celltech Ltd | Pharmaceutical product |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
SG63617A1 (en) | 1991-01-18 | 1999-03-30 | Amgen Boulder Inc | Methods for treating tumar necrosis factor mediated diseases |
SG47099A1 (en) | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
DK0594772T3 (pt) | 1991-07-04 | 1997-02-24 | Immunodex K S | |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
NZ256293A (en) * | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5723116A (en) * | 1995-01-06 | 1998-03-03 | University Of South Florida | Decreased mortality of severe acute pancreatitis following proximal cytokine blockade |
US6096728A (en) * | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
-
1997
- 1997-12-08 AU AU56961/98A patent/AU5696198A/en not_active Abandoned
- 1997-12-08 JP JP52589398A patent/JP2001513754A/ja not_active Ceased
- 1997-12-08 DE DE69724451T patent/DE69724451T2/de not_active Expired - Lifetime
- 1997-12-08 DK DK97953156T patent/DK0942740T3/da active
- 1997-12-08 PT PT97953156T patent/PT942740E/pt unknown
- 1997-12-08 CA CA002273850A patent/CA2273850A1/en not_active Abandoned
- 1997-12-08 WO PCT/US1997/022733 patent/WO1998024463A2/en active IP Right Grant
- 1997-12-08 EP EP97953156A patent/EP0942740B1/en not_active Expired - Lifetime
- 1997-12-08 ES ES97953156T patent/ES2207759T3/es not_active Expired - Lifetime
- 1997-12-08 AT AT97953156T patent/ATE247974T1/de active
-
1999
- 1999-06-04 US US09/326,394 patent/US6306820B1/en not_active Expired - Fee Related
-
2000
- 2000-03-17 HK HK00101650A patent/HK1022440A1/xx not_active IP Right Cessation
-
2001
- 2001-07-17 US US09/907,263 patent/US20020119924A1/en not_active Abandoned
-
2003
- 2003-07-16 US US10/622,383 patent/US20040048799A1/en not_active Abandoned
- 2003-07-16 US US10/621,783 patent/US20040047863A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2001513754A (ja) | 2001-09-04 |
WO1998024463A2 (en) | 1998-06-11 |
US20020119924A1 (en) | 2002-08-29 |
US20040047863A1 (en) | 2004-03-11 |
EP0942740B1 (en) | 2003-08-27 |
DK0942740T3 (da) | 2003-12-15 |
EP0942740A2 (en) | 1999-09-22 |
WO1998024463A3 (en) | 1998-07-16 |
DE69724451T2 (de) | 2004-03-18 |
US6306820B1 (en) | 2001-10-23 |
DE69724451D1 (de) | 2003-10-02 |
HK1022440A1 (en) | 2000-08-11 |
CA2273850A1 (en) | 1998-06-11 |
ES2207759T3 (es) | 2004-06-01 |
US20040048799A1 (en) | 2004-03-11 |
ATE247974T1 (de) | 2003-09-15 |
AU5696198A (en) | 1998-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT942740E (pt) | Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf | |
BRPI0410129A (pt) | uso terapêutico de anticorpos anti-cs1 | |
CY1118429T1 (el) | Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου | |
BG110703A (en) | PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION | |
BR0011000A (pt) | Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico | |
DE69533855D1 (de) | UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG | |
BRPI0407058A (pt) | Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento | |
ATE326239T1 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
DE69703689D1 (de) | Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia | |
DE69927147D1 (de) | Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
SE9603725D0 (sv) | New teatment | |
BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
PT1128841E (pt) | Composicao farmaceutica contendo um antagonista de receptor para o tratamento de disturbios da coagulacao sanguinea | |
BR9708037A (pt) | Método para o tratamento de abuso de substância | |
BR9801839A (pt) | Medicamento analgésico e aplicação de (+) -0-demetiltramadol. | |
EA200200559A1 (ru) | Способ лечения и профилактики нейродегенеративных состояний | |
MXPA03010451A (es) | Nuevos metodos para el tratamiento y prevencion del dolor. | |
EP1352656A3 (en) | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | |
UA29709A (uk) | Спосіб лікування захворювань гастродуоденальної системи та суміш для його здійснення |